British Patient Capital’s Future Fund: Breakthrough Scheme

Ashurst has advised British Patient Capital on the Future Fund: Breakthrough scheme.

Future Fund: Breakthrough is a new £375m UK-wide scheme that encourages private investors to co-invest in high-growth, innovative UK companies that invest heavily in research and development (R&D).

The scheme launched in July 2021 and is delivered by British Patient Capital, a commercial subsidiary of British Business Bank. It will crowd in private-sector investment to support the growth of those companies whose applications to the scheme are successful.

These R&D-intensive companies accelerate the deployment of breakthrough technologies which can transform major industries, develop new medicines and support the UK’s transition to a net zero economy.

The Ashurst’s team advising British Patient Capital comprised partner Karen Davies (Picture), senior associate Jacob Gold and associate Amy Coleman.  

Involved fees earner: Amy Coleman – Ashurst; Karen Davies – Ashurst; Jacob Gold – Ashurst;

Law Firms: Ashurst;

Clients: British Patient Capital;

Federica Tiefenthaler

Author: Federica Tiefenthaler